Related Experiment Videos
A practical guide to targeted therapy for bone pain palliation.
1Nuclear Medicine Department, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK. vjlewington@hotmail.com
Nuclear Medicine Communications
|August 27, 2002
Summary
Targeted radionuclide therapy offers effective, cost-efficient treatment for bone pain from metastatic cancer. This review details radiopharmaceuticals like samarium-153 EDTMP, rhenium-186 HEDP, and strontium-89 chloride, guiding clinical choices and patient selection for optimal outcomes.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical therapy
Background:
- Metastatic bone pain significantly impacts patient quality of life.
- Targeted radionuclide therapy presents a cost-effective treatment option for widespread bone metastases.
Framework:
- This paper reviews three key radiopharmaceuticals: samarium-153 ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) ((153)Sm-EDTMP), rhenium-186 1,1-hydroxyethylidenediphosphonate ((186)Re-HEDP), and strontium-89 chloride ((89)SrCl2).
- It examines the physical characteristics of these agents relevant to clinical application.
Implementation:
- Factors influencing the choice of radiopharmaceutical in specific clinical scenarios are discussed.
- Criteria for patient selection and methods for monitoring treatment response are outlined.
- Practical advantages and limitations of targeted radionuclide therapy are considered.
Implications:
- Optimizing patient selection and response monitoring can enhance therapeutic efficacy.
- Further research is needed to expand the applications and refine the use of targeted radionuclide therapy.
- This approach offers a valuable palliative option for managing metastatic bone pain.